Brief: Successful Readout Of Prospective Phase 2 Sinergy Trial Supports Signateratm Mrd-Guided Treatment
24/02/2026 11:07
Feb 24 (Reuters) - Natera Inc NTRA.O: SUCCESSFUL READOUT OF PROSPECTIVE PHASE 2 SINERGY TRIAL SUPPORTS SIGNATERATM MRD-GUIDED TREATMENT IN HEAD AND NECK CANCER NATERA INC - TRIAL ACHIEVES 63% RESPONSE RATE, REDUCES CHEMOTHERAPY IN 74% OF PATIENTS Source text: ID:nBw9RC2v6a Further company coverage: NTRA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Natera
See all newsBrief: FDA Grants Breakthrough Device Designation For Natera’S Multi-Cancer Early Detection Assay
Brief: Alliance Foundation Trials And Natera Announce Aft-70 Navigate A Global, Randomized, Phase Iii Trial Evaluating Genentech’S Oral Selective Estrogen Receptor Degrader With Signatera Mrd-Guided Cdk4/6 Inhibitor Therapy In Breast Cancer
US RESEARCH ROUNDUP-Chevron, Exxon Mobil, GoDaddy
Brief: Natera Says Signatera Commercial Launch In Japan Expected In 1H 2027
Brief: Natera To Support New Clinical Trial Assessing Ctdna Dynamics With Latitud In Advanced Skin Cancers